Further, it is also an approved drug by USFDA in treating conditions such as idiopathic epilepsy, CDKL5 deficiency, resistant Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This evidence concerns the gene CDKL5 and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.